Source comparison
Ipamorelin vs CJC-1295: Comparing GH Secretagogue Approaches to Somatopause and Longevity Research UK 2026
Research Use Only. Not for human or veterinary therapeutic use. All content is provided for scientific reference and educational purposes only. Ipamorelin and CJC-1295 DAC represent two of the most studied growth hormone (GH) axis research compounds — but they
This comparison does not assign a generated winner or score.
- Research Use Only. Not for human or veterinary therapeutic use. All content is provided for scientific reference and educational purposes only.
- Ipamorelin and CJC-1295 DAC represent two of the most studied growth hormone (GH) axis research compounds — but they act through fundamentally different receptor systems, produce distinct GH pulse dynamics, and carry different research implications for somatopause reversal and longevity biology. Ipamorelin is a selective GHS-R1a (ghrelin receptor) agonist; CJC-1295 DAC is a long-acting GHRH receptor (GHRHR) agonist. Understanding these mechanistic differences is essential for selecting the appropriate compound — or combination — for a given research programme in GH axis ageing biology.